TauRx Therapeutics Ltd.

TauRx Therapeutics Ltd. is planning to file its anti-tau drug candidate, hydromethylthionine mesylate (HMTM), for the treatment of Alzheimer’s disease following data from the Phase III LUCIDITY trial

All eyes will be on the first presentation of detailed results for Eisai Co., Ltd. / Biogen, Inc. ’s amyloid-clearing antibody lecanemab from the Phase III Clarity AD trial at the Clinical Trials on

CG Oncology, Inc. led the latest group of private biotechnology companies that completed $100m-plus venture capital mega-rounds, with a $120m series E financing announced on 15 November, followed clo

TauRx Therapeutics Ltd. ’s tau aggregation inhibitor candidate for Alzheimer’s has improved cognitive and functional decline rates according to initial data from a late-stage trial but the lack of num